Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Distinct trajectory and prognosis of measurable residual disease (MRD) in t(11;14) multiple myeloma (MM) treated with upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)

Luciano Costa, Kelly Godby, Gayathri Ravi, Forest Huls, Eva Medvedova, Binod Dhakal, Bhagirathbhai Dholaria, Natalie Callander, Rebecca Silbermann, Laura Joiner, Caitlin Hagedorn, Baylie Mullinax, Susan Bal

Blood (2025) 146 (Supplement 1): 363.

https://doi.org/10.1182/blood-2025-363

Published: 2025

Journal Articles

Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study

Blood (2025) 146 (Supplement 1): 97.

https://doi.org/10.1182/blood-2025-97

Published: 2025

Journal Articles

Redefining function high-risk (FHR) multiple myeloma (MM) in the context of upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)

Luciano Costa, Susan Bal, Kelly Godby, Gayathri Ravi, Eva Medvedova, Natalie Callander, Rebecca Silbermann, Bhagirathbhai Dholaria, Forest Huls, Baylie Mullinax, Laura Joiner, Caitlin Hagedorn, Binod Dhakal

Blood (2025) 146 (Supplement 1): 1037.

https://doi.org/10.1182/blood-2025-1037

Published: 2025

Journal Articles

A functional precision medicine clinical trial in Relapsed/Refractory multiple myeloma: Prospective study of a high throughput drug sensitivity assay on correlation of drug sensitivity scores with treatment response

Raffaella Cassano Cassano, Timothy Martins, David Coffey, Gabriele Buda, Sara Galimberti, Ryan Donnelly, Mary Kwok, Damian Green, Rahul Banerjee, Kara Cicero, Ted Gooley, Rebecca Silbermann, Pamela Becker, Andrew Cowan

Blood (2025) 146 (Supplement 1): 7446.

https://doi.org/10.1182/blood-2025-7446

Published: 2025

Journal Articles

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Blood (2025) 146 (Supplement 1): 928.

https://doi.org/10.1182/blood-2025-928

Published: 2025

Journal Articles

Characterization of a population with newly diagnosed standard risk multiple myeloma by the 2025 ims/IMWG definition with exceptional long-term outcomes after fixed duration therapy

Eva Medvedova, Bhagirathbhai Dholaria, Gayathri Ravi, Binod Dhakal, Rebecca Silbermann, Susan Bal, Kelly Godby, Laura Joiner, Natalie Callander, Luciano Costa

Blood (2025) 146 (Supplement 1): 4007.

https://doi.org/10.1182/blood-2025-4007

Published: 2025

Journal Articles

Outcomes of patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant stratified by the 2025 ims/IMWG risk classification

Priyanka Venkatesh, Gayathri Ravi, Kelly Godby, Binod Dhakal, Eva Medvedova, Rebecca Silbermann, Bhagirathbhai Dholaria, Forest Huls, Laura Joiner, Caitlin Hagedorn, Natalie Callander, Luciano Costa, Susan Bal

Blood (2025) 146 (Supplement 1): 5799.

https://doi.org/10.1182/blood-2025-5799

Published: 2025

Journal Articles

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Blood (2025) 145 (3): 300–310.

https://doi.org/10.1182/blood.2024025746

Published: 2025

Includes: Supplemental data

Journal Articles

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Blood (2024) 144 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2024-199733

Published: 2024

Journal Articles

Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups

Blood (2024) 144 (Supplement 1): 675.

https://doi.org/10.1182/blood-2024-201736

Published: 2024

Journal Articles

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Blood (2024) 144 (Supplement 1): 2000.1.

https://doi.org/10.1182/blood-2024-200210

Published: 2024

Journal Articles

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2023-173202

Published: 2023

Journal Articles

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Blood (2023) 142 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2023-179170

Published: 2023

Journal Articles

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Blood (2023) 142 (Supplement 1): 4746.

https://doi.org/10.1182/blood-2023-177968

Published: 2023

Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Blood (2022) 140 (Supplement 1): 10144–10147.

https://doi.org/10.1182/blood-2022-160451

Published: 2022

Journal Articles

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Timothy Martin Schmidt, Bhagirathbhai Dholaria, Kelly N. Godby, Rebecca Silbermann, Susan Bal, Anita D'Souza, Smith Giri, James L. Omel, Parameswaran Hari, Natalie Callander, Binod Dhakal

Blood (2022) 140 (Supplement 1): 7275–7277.

https://doi.org/10.1182/blood-2022-156730

Published: 2022

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Are Triple-Class Exposed to an Immunomodulatory Agent, a Proteasome Inhibitor, and an Anti-CD38 Antibody

Nina Shah, Ravi Vij, Jenna S. Roberts, Ivana Rajkovic, Rebecca Silbermann, Jens Hillengass, Sujith Dhanasiri, Julia Braverman, Abigail McMillan, Devender Dhanda

Blood (2022) 140 (Supplement 1): 13259–13261.

https://doi.org/10.1182/blood-2022-158235

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Blood (2022) 140 (Supplement 1): 7278–7281.

https://doi.org/10.1182/blood-2022-162339

Published: 2022

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Blood (2022) 140 (Supplement 1): 1146–1149.

https://doi.org/10.1182/blood-2022-162313

Published: 2022

Journal Articles

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Smith Giri, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy Martin Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Anita D'Souza, Aric C. Hall, Pamela Hardwick, Jim Omel, Robert Frank Cornell, Natalie Callander, Parameswaran Hari, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 4431–4433.

https://doi.org/10.1182/blood-2022-160381

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Distinct trajectory and prognosis of measurable residual disease (MRD) in t(11;14) multiple myeloma (MM) treated with upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)

Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the auriga study

Redefining function high-risk (FHR) multiple myeloma (MM) in the context of upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)

A functional precision medicine clinical trial in Relapsed/Refractory multiple myeloma: Prospective study of a high throughput drug sensitivity assay on correlation of drug sensitivity scores with treatment response

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Characterization of a population with newly diagnosed standard risk multiple myeloma by the 2025 ims/IMWG definition with exceptional long-term outcomes after fixed duration therapy

Outcomes of patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant stratified by the 2025 ims/IMWG risk classification

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-up and Selected High-Risk Subgroup Analyses of the Linker-MM1 Study

Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment

Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Are Triple-Class Exposed to an Immunomodulatory Agent, a Proteasome Inhibitor, and an Anti-CD38 Antibody

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only